Carmat said its artificial heart would be marketed under the brand name of "Aeson". Aeson would be launched commercially in Germany in the second quarter, while the French market would be targeted around the same time. Carmat shares were up by around 7% in early session trading, giving the company a market capitalisation of around 400 million euros ($493.3 million). "I am happy to confirm that we will be ready to start selling our product as early as Q2 2021," said Carmat Chief Executive Stephane Piat. Airbus' subsidiary Matra Defense owns a 13% stake in Carmat, while the ALIAD venture capital unit of Air Liquide has a 0.6% stake.

Source: bd News24 January 06, 2021 08:15 UTC